High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Kim, Ekaterina [1 ]
Sivina, Mariela [1 ]
Vaca, Alicia [1 ]
Ferrajoli, Alessandra [1 ]
Jain, Nitin [2 ]
Thompson, Philip A. [1 ]
Wierda, William G. [1 ]
Wodarz, Dominik [3 ]
Chiorazzi, Nicholas [4 ]
Burger, Jan A. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[3] Univ Calif Irvine, Irvine, CA USA
[4] Feinstein Inst Med Res, Karches Ctr Oncol Res, Manhasset, NY USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-160238
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4140 / 4141
页数：2
相关论文
共 50 条
  • [41] Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy
    Jones, Jeffrey A.
    Hillmen, Peter
    Coutre, Steven
    Tam, Constantine
    Furman, Richard R.
    Barr, Paul M.
    Schuster, Stephen J.
    Kipps, Thomas J.
    Flinn, Ian W.
    Jaeger, Ulrich
    Burger, Jan A.
    Cheng, Mei
    Lee, Dana
    James, Danelle F.
    Byrd, John C.
    O'Brien, Susan
    BLOOD, 2014, 124 (21)
  • [42] Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia
    Stankowicz, Matthew
    Banaszynski, Megan
    Crawford, Russell
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 710 - 714
  • [43] NAIL AND HAIR CHANGES DURING IBRUTINIB THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
    Mauro, F. R.
    Porrazzo, M.
    Bottoni, U.
    Riemma, C.
    Raponi, S.
    Guarini, A.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 122 - 122
  • [44] Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
    Mahlich J.
    Okamoto S.
    Tsubota A.
    PharmacoEconomics - Open, 2017, 1 (3) : 195 - 202
  • [45] Achievement of complete remission (CR) as an endpoint for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib.
    Strati, Paolo
    Sivina, Mariela
    Kim, Ekaterina
    Keating, Michael J.
    Wierda, William G.
    Ferrajoli, Alessandra
    Kantarjian, Hagop M.
    Estrov, Zeev
    Jain, Nitin
    Thompson, Philip A.
    Burger, Jan Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings
    Hou, Jing-Zhou
    Ryan, Kellie
    Du, Senxi
    Fang, Bruno S.
    Marks, Stanley M.
    Page, Ray
    Peng, Eileen
    Szymanski, Keith
    Winters, Sharon
    Le, Hannah
    BLOOD, 2020, 136
  • [47] Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
    Liu, Yanyan
    Song, Yongping
    Yin, Qingsong
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [48] FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL).
    O'Brien, S
    Wierda, WG
    Faderl, S
    Ferrajoli, A
    Bueso-Ramos, CE
    Browning, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2005, 106 (11) : 599A - 599A
  • [49] Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
    Ferrajoli, Alessandra
    Badoux, Xavier C.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lee, Bang-Ning
    Reuben, James M.
    Kantarjian, Hagop
    Keating, Michael
    BLOOD, 2009, 114 (22) : 89 - 90
  • [50] Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation
    Barrientos, Jacqueline C.
    Kaur, Manmeen
    Mark, Alexis
    Chung, Jaewon
    Driscoll, Nancy
    Bender, Alison
    Rai, Kanti R.
    BLOOD, 2015, 126 (23)
12345